Stempoint Capital’s CytomX Therapeutics CTMX Stock Holding History

Stempoint Capital’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,036,311	Closed	-$4.41M	–	94
2025 Q4	$4.41M	Buy	+1,036,311	New	+$3.94M	0.76%	45

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stempoint Capital's CTMX Position: Q1 2026 in Review

Stempoint Capital sold out of CytomX Therapeutics (CTMX) in Q1 2026, closing a stake of 1,036,311 shares — an estimated $4.41M sold.

Stempoint Capital first reported a position in CTMX in Q4 2025 and held it in 1 quarter. The position peaked at $4.41M in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

Stempoint Capital reported no remaining CytomX Therapeutics position as of Q1 2026 after selling out during the quarter.
Stempoint Capital sold 1,036,311 CytomX Therapeutics shares in Q1 2026, an estimated $4.41M.
Stempoint Capital first reported a position in CytomX Therapeutics in Q4 2025 and held it in 1 quarter.
Stempoint Capital's CytomX Therapeutics position peaked at $4.41M in Q4 2025.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.